- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Calidi presents cancer therapy data at AACR meeting | 3 | Investing.com | ||
| Mo | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 | 1 | GlobeNewswire (USA) | ||
| 14.04. | Calidi to present RedTail platform data at Iceland conference | 2 | Investing.com | ||
| 27.03. | Calidi Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| CALIDI BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Calidi Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Calidi BioTherapeutics GAAP EPS of -$5.95 | 2 | Seeking Alpha | ||
| 27.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights | 148 | GlobeNewswire (Europe) | Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its... ► Artikel lesen | |
| 24.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials | 1 | GlobeNewswire (USA) | ||
| 12.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company's Approach to Manufacturing | 1 | GlobeNewswire (USA) | ||
| 10.03. | Calidi Biotherapeutics closes $6M public offering | 1 | Investing.com | ||
| 10.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option | 1 | GlobeNewswire (USA) | ||
| 06.03. | Calidi BioTherapeutics prices $5.2M underwritten public offering | 1 | Seeking Alpha | ||
| 06.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering | 2 | GlobeNewswire (USA) | ||
| 06.03. | Calidi Biotherapeutics (CLDI) Stock Plunges 35% After Hours - Here's Why | 1 | Benzinga.com | ||
| 06.03. | Calidi Biotherapeutics announces underwritten public offering | 1 | Investing.com | ||
| 06.03. | Calidi BioTherapeutics plans public offering of stock, pre-funded warrants; shares down | 1 | Seeking Alpha | ||
| 06.03. | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Announces Proposed Public Offering | 148 | GlobeNewswire (Europe) | SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic... ► Artikel lesen | |
| 05.12.25 | RedChip Companies, Inc.: Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TV | 494 | ACCESS Newswire | ORLANDO, FLORIDA / ACCESS Newswire / December 5, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Nova Minerals Limited (Nasdaq:NVA) on the RedChip... ► Artikel lesen | |
| 13.11.25 | Calidi BioTherapeutics GAAP EPS of -$2.21 misses by $0.53 | 1 | Seeking Alpha | ||
| 13.11.25 | Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights | 489 | GlobeNewswire (Europe) | Presented new data at the Society of Immunotherapy for Cancer (SITC) annual meeting on CLD-401 protection from immune clearance after systemic administration; data also demonstrates that the platform... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| OCUGEN | 1,414 | -0,56 % | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead | ||
| VIKING THERAPEUTICS | 28,050 | +0,18 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 3,545 | 0,00 % | Truist reiterates Buy on AbCellera stock ahead of 2H26 data | ||
| ADAPTIMMUNE THERAPEUTICS | 0,013 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 5,040 | +0,80 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer | SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential |
Das Unternehmen CALIDI BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,222 Euro und damit +1,93 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALIDI BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.